TrialHaematologica2023

Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.

Jonathan A Gutman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.